Different Doses of IVIG for Kawasaki Disease
NCT02439996 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 404
Last updated 2018-05-11
Summary
The objective of this study is to investigate the effect of different doses of intravenous immunoglobulin (IVIG) (1g/kg once, 1g/kg twice, 2g/kg once) for Kawasaki disease (KD) in a multicentre, prospective,randomised trial.
Conditions
- Kawasaki Disease
Interventions
- DRUG
-
IVIG (1g/kg,once)
Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h. Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
- DRUG
-
IVIG (1g/kg,twice)
Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h. Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
- DRUG
-
IVIG (2g/kg.once)
Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h. Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Sponsors & Collaborators
-
Shanghai Children's Medical Center
collaborator OTHER -
Shanghai Children's Hospital
collaborator OTHER -
Children's Hospital of Fudan University
lead OTHER
Principal Investigators
-
Guoying Huang, PHD · Children Hospital of Fudan University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Month
- Max Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2016-03-31
- Completion
- 2016-09-30
Countries
- China
Study Locations
More Related Trials
-
Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age
NCT03481894 ·Status: WITHDRAWN ·Phase: PHASE4
-
IV Glucose for Dehydration Treatment
NCT01285713 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
NCT04944979 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Use of Corticosteroids in Children With Cellulitis
NCT02087527 ·Status: TERMINATED ·Phase: NA
-
Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support
NCT02980666 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm
NCT04850456 ·Status: RECRUITING
-
LASER THERAPY IN GASTRIC STOMA INJURIES OF CHILDREN AND ADOLESCENTS
NCT04863196 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
NCT02899702 ·Status: WITHDRAWN ·Phase: PHASE4
-
Subcutaneous Nitroglycerin to Prevent Radial Artery Occlusion in Children
NCT05443061 ·Status: COMPLETED ·Phase: NA
-
Implementation of an Infusion Management Scheme to Improve Patient Outcome in Tertiary Children's Hospitals
NCT05152446 ·Status: TERMINATED ·Phase: NA
-
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
NCT05027308 ·Status: COMPLETED ·Phase: PHASE3
-
Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants
NCT07254000 ·Status: RECRUITING ·Phase: PHASE2
-
Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children
NCT01343758 ·Status: COMPLETED ·Phase: NA
-
Sugammadex Versus Neostigmine in Pediatric Less Than Two Years Undergoing Cardiac Catheterization
NCT04258007 ·Status: COMPLETED ·Phase: NA
-
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
NCT06127381 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency
NCT00004386 ·Status: TERMINATED ·Phase: PHASE1
-
Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin
NCT04986735 ·Status: UNKNOWN
-
Efficacy and Safety of the Algorithm for Enteral Nutrition Support
NCT04609358 ·Status: COMPLETED ·Phase: NA
-
Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children
NCT01757899 ·Status: WITHDRAWN ·Phase: PHASE2
-
Subcutaneous Nitroglycerin for Pediatric Radial Artery Cannulation
NCT03849183 ·Status: COMPLETED ·Phase: NA
-
Pharmacology of Exenatide in Pediatric Sepsis
NCT01573806 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
NCT01952080 ·Status: COMPLETED ·Phase: PHASE3
-
ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
NCT04434001 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers
NCT01640990 ·Status: COMPLETED ·Phase: PHASE1
-
Using Lignocaine Spray and Gel to Reduce the Pain Associated With Nasogastric Tube Insertion in Children
NCT01075789 ·Status: TERMINATED ·Phase: NA